These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 21211492)

  • 1. Utility values in National Institute for Health and Clinical Excellence (NICE) Technology Appraisals.
    Tosh JC; Longworth LJ; George E
    Value Health; 2011 Jan; 14(1):102-9. PubMed ID: 21211492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How Do Pharmaceutical Companies Model Survival of Cancer Patients? A Review of NICE Single Technology Appraisals in 2017.
    Gallacher D; Auguste P; Connock M
    Int J Technol Assess Health Care; 2019 Jan; 35(2):160-167. PubMed ID: 31017564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The estimation of health state utility values in rare diseases: do the approaches in submissions for NICE technology appraisals reflect the existing literature? A scoping review.
    Meregaglia M; Nicod E; Drummond M
    Eur J Health Econ; 2023 Sep; 24(7):1151-1216. PubMed ID: 36335234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inclusion of Carer Health-Related Quality of Life in National Institute for Health and Care Excellence Appraisals.
    Pennington BM
    Value Health; 2020 Oct; 23(10):1349-1357. PubMed ID: 33032779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What value health?: A review of health state values used in early technology assessments for NICE.
    Stein K; Fry A; Round A; Milne R; Brazier J
    Appl Health Econ Health Policy; 2005; 4(4):219-28. PubMed ID: 16466273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Review of the Methods Used to Generate Utility Values in NICE Technology Assessments for Children and Adolescents.
    Hill H; Rowen D; Pennington B; Wong R; Wailoo A
    Value Health; 2020 Jul; 23(7):907-917. PubMed ID: 32762993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health-state utility estimates for health technology assessment: a review of the manufacturers' submissions to the French National Authority for Health.
    Hamers FF; Ghabri S; Le Gales C
    Expert Rev Pharmacoecon Outcomes Res; 2017 Oct; 17(5):489-494. PubMed ID: 28133977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Impact of Moving from EQ-5D-3L to -5L in NICE Technology Appraisals.
    Pennington B; Hernandez-Alava M; Pudney S; Wailoo A
    Pharmacoeconomics; 2019 Jan; 37(1):75-84. PubMed ID: 30094806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What Is the Evidence from Past National Institute of Health and Care Excellence Single-Technology Appraisals Regarding Company Submissions with Base-Case Incremental Cost-Effectiveness Ratios of Less Than £10,000/QALY?
    Carroll C; Houten R; Boland A; Kaltenthaler E; Dickson R
    Value Health; 2018 Mar; 21(3):341-350. PubMed ID: 29566842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic reviews and economic evaluations conducted for the National Institute for Health and Clinical Excellence in the United Kingdom: a game of two halves?
    Drummond MF; Iglesias CP; Cooper NJ
    Int J Technol Assess Health Care; 2008; 24(2):146-50. PubMed ID: 18400116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of exploratory analyses within the National Institute for Health and Care Excellence single technology appraisal process: an evaluation and qualitative analysis.
    Kaltenthaler E; Carroll C; Hill-McManus D; Scope A; Holmes M; Rice S; Rose M; Tappenden P; Woolacott N
    Health Technol Assess; 2016 Apr; 20(26):1-48. PubMed ID: 27049841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence Review Group approaches to the critical appraisal of manufacturer submissions for the NICE STA process: a mapping study and thematic analysis.
    Kaltenthaler E; Boland A; Carroll C; Dickson R; Fitzgerald P; Papaioannou D
    Health Technol Assess; 2011 May; 15(22):1-82, iii-iv. PubMed ID: 21561569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploration of the difference in results of economic submissions to the National Institute of Clinical Excellence by manufacturers and assessment groups.
    Chauhan D; Miners AH; Fischer AJ
    Int J Technol Assess Health Care; 2007; 23(1):96-100. PubMed ID: 17234022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seeing the NICE side of cost-effectiveness analysis: a qualitative investigation of the use of CEA in NICE technology appraisals.
    Bryan S; Williams I; McIver S
    Health Econ; 2007 Feb; 16(2):179-93. PubMed ID: 16960851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methodological issues in undertaking independent cost-effectiveness analysis for NICE: the case of therapies for ADHD.
    Griffin SC; Weatherly HL; Richardson GA; Drummond MF
    Eur J Health Econ; 2008 May; 9(2):137-45. PubMed ID: 17476538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of Economic Submissions to NICE Medical Technologies Evaluation Programme.
    Alshreef A; Jenks M; Green W; Dixon S
    Appl Health Econ Health Policy; 2016 Dec; 14(6):623-634. PubMed ID: 27480537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in the measurement of health utilities in published cost-utility analyses.
    Brauer CA; Rosen AB; Greenberg D; Neumann PJ
    Value Health; 2006; 9(4):213-8. PubMed ID: 16903990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does Methodological Guidance Produce Consistency? A Review of Methodological Consistency in Breast Cancer Utility Value Measurement in NICE Single Technology Appraisals.
    Rose M; Rice S; Craig D
    Pharmacoecon Open; 2018 Jun; 2(2):97-107. PubMed ID: 29623616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A little learning: reflections on 10 years of NICE technology appraisals.
    Longson CM
    Health Econ; 2012 Jan; 21(1):30-2. PubMed ID: 22147626
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.